Galectin Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Galectin Therapeutics Inc.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
After raising nearly $330m this year, via a financing and IPO, the company is gearing up for a first-in-human trial using its platform technology.
The latest financing round will also support a new clinical trial of the RNS system for children with epilepsy.
Formycon has pushed its second ophthalmology biosimilar candidate into Phase III trials, the German firm’s Eylea (aflibercept) biosimilar, FYB203, which has been licensed to Bioeq. Multiple firms are now circling Eylea, ahead of a projected US market formation in 2023.
- Drug Delivery
- Other Names / Subsidiaries
- Galectin Sciences, LLC
- Pro-Pharmaceuticals Inc.
- Galectin Therapeutics Security Corp.